Table 2 Investigational parameters at baseline, after 12 and 24 weeks of treatment in the observational groups
Baseline | 12 weeks | 24 weeks | ||||
|---|---|---|---|---|---|---|
Glimepiride | Vildagliptin | Glimepiride | Vildagliptin | Glimepiride | Vildagliptin | |
HbA1c (%) | 7.28 ± 0.59 | 7.41 ± 0.74 | 6.70 ± 0.50 * | 6.95 ± 0.82 * | 6.57 ± 0.45 * | 6.74 ± 0.75 * |
Fasting BG (mmol/L) | 8.2 ± 1.9 | 8.4 ± 1.5 | 7.0 ± 1.2 * | 7.6 ± 1.9 | 7.0 ± 1.2 * | 7.4 ± 1.4 * |
Adiponectin (μg/mL) | 5.6 ± 3.1 | 5.0 ± 3.5 | 5.4 ± 2.8 | 5.5 ± 4.1 | 5.7 ± 2.7 | 5.7 ± 4.1 * |
Body weight (kg) | 93.7 ± 19.6 | 99.3 ± 14.9 | 94.4 ± 18.9 | 98.7 ± 15.0 | 95.5 ± 19.0 | 97.6 ± 14.3 * |
RBF (AU) | 74.2 ± 5.3 | 75.1 ± 5.8 | 74.7 ± 6.9 | 75.3 ± 5.8 | 76.1 ± 7.6 | 77.9 ± 5.9 * |
WLR (AU) | 0.47 ± 0.08 | 0.46 ± 0.06 | 0.45 ± 0.09 | 0.43 ± 0.07 | 0.43 ± 0.08 | 0.40 ± 0.06 * |
EI AUC0.3–60 (AU*min) | 2536 ± 228 | 2568 ± 196 | 2505 ± 256 | 2570 ± 170 | 2682 ± 240 * | 2623 ± 210 * |